Inflammatory markers, such as leukocyte count at admission, serve as powerful predictors of adverse outcomes including ventricular remodeling, heart failure, and sudden death after STEMI.
Do inflammatory markers predict adverse outcomes in patients with ST-elevation acute myocardial infarction?
Inflammatory markers can identify STEMI patients at greater risk of adverse events like heart failure and sudden death, providing insight into disease progression.
After acute myocardial infarction, ventricular remodeling is characterized by changes at the molecular, structural, geometrical and functional level that determine progression to heart failure. Inflammation plays a key role in wound healing and scar formation, affecting ventricular remodeling. Several, rather different, components of the inflammatory response were studied as biomarkers in ST-elevation acute myocardial infarction. Widely available and inexpensive tests, such as leukocyte count at admission, as well as more sophisticated immunoassays provide powerful predictors of adverse outcome in patients with ST-elevation acute myocardial infarction. We review the value of inflammatory markers in ST-elevation acute myocardial infarction and their association with ventricular remodeling, heart failure and sudden death. In conclusion, the use of these biomarkers may identify subjects at greater risk of adverse events and perhaps provide an insight into the mechanisms of disease progression.
Seropián et al. (Fri,) conducted a review in ST-elevation acute myocardial infarction. Inflammatory markers was evaluated. Inflammatory markers, such as leukocyte count at admission, serve as powerful predictors of adverse outcomes including ventricular remodeling, heart failure, and sudden death after STEMI.